Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome
Name
Bear_Lovastatin_corrects.pdf
Size
1.4 MB
Format
Adobe PDF
Checksum (MD5)
515014fd07d3447810fd42fd95868122
Author(s)
Chuang, Shih-Chieh
Chubykin, Alexander A.
Sidorov, Michael
Bianchi, Riccardo
Wong, Robert K.S.
Osterweil, Emily
Bear, Mark
Chubykin, Alexander A.
Date Issued
January 2013
Journal
Neuron
Publisher
Elsevier
Citation
Osterweil, Emily K., Shih-Chieh Chuang, Alexander A. Chubykin, Michael Sidorov, Riccardo Bianchi, Robert K.S. Wong, and Mark F. Bear. “Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome.” Neuron 77, no. 2 (January 2013): 243–250.
Version
Author's final manuscript
Abstract
Many neuropsychiatric symptoms of fragile X syndrome (FXS) are believed to be a consequence of altered regulation of protein synthesis at synapses. We discovered that lovastatin, a drug that is widely prescribed for the treatment of high cholesterol, can correct excess hippocampal protein synthesis in the mouse model of FXS and can prevent one of the robust functional consequences of increased protein synthesis in FXS, epileptogenesis. These data suggest that lovastatin is potentially disease modifying and could be a viable prophylactic treatment for epileptogenesis in FXS.
MIT Department
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution-Noncommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.neuron.2012.01.034
